Michael Price decreased its stake in Hess Corporation (HES) by 27.72% based on its latest 2017Q3 regulatory filing with the SEC. Price Michael F sold 140,000 shares as the company’s stock declined 5.45% while stock markets rallied. The hedge fund run by Michael Price held 365,000 shares of the integrated oil company at the end of 2017Q3, valued at $17.12M, down from 505,000 at the end of the previous reported quarter. Price Michael F who had been investing in Hess Corporation for a number of months, seems to be less bullish one the $15.21 billion market cap company. The stock increased 1.68% or $0.79 during the last trading session, reaching $47.87. About 4.43M shares traded. Hess Corporation (NYSE:HES) has declined 14.55% since February 25, 2017 and is downtrending. It has underperformed by 31.25% the S&P500.
Essex Woodlands Health Ventures Inc decreased its stake in Abiomed Inc (ABMD) by 34.7% based on its latest 2017Q3 regulatory filing with the SEC. Essex Woodlands Health Ventures Inc sold 503,182 shares as the company’s stock rose 15.32% with the market. The hedge fund held 946,818 shares of the health care company at the end of 2017Q3, valued at $159.63M, down from 1.45 million at the end of the previous reported quarter. Essex Woodlands Health Ventures Inc who had been investing in Abiomed Inc for a number of months, seems to be less bullish one the $11.89B market cap company. The stock increased 1.70% or $4.48 during the last trading session, reaching $268.45. About 367,297 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 40.97% since February 25, 2017 and is uptrending. It has outperformed by 24.27% the S&P500.
Among 22 analysts covering Hess Corp. (NYSE:HES), 9 have Buy rating, 2 Sell and 11 Hold. Therefore 41% are positive. Hess Corp. had 62 analyst reports since July 22, 2015 according to SRatingsIntel. JP Morgan upgraded the stock to “Overweight” rating in Thursday, December 8 report. The firm earned “Equal Weight” rating on Tuesday, January 12 by Barclays Capital. Wolfe Research upgraded Hess Corporation (NYSE:HES) on Tuesday, April 11 to “Outperform” rating. The stock has “Buy” rating by Piper Jaffray on Tuesday, February 6. Cowen & Co maintained the shares of HES in report on Tuesday, January 16 with “Hold” rating. The firm has “Buy” rating by Societe Generale given on Friday, July 31. Credit Suisse downgraded it to “Neutral” rating and $65 target in Thursday, April 28 report. The firm earned “Neutral” rating on Wednesday, December 9 by JP Morgan. Zacks downgraded the shares of HES in report on Saturday, August 8 to “Buy” rating. The firm earned “Hold” rating on Friday, September 1 by BMO Capital Markets.
Since August 24, 2017, it had 0 insider purchases, and 8 sales for $5.29 million activity. $255,180 worth of Hess Corporation (NYSE:HES) was sold by Truelove Brian D.. Another trade for 4,567 shares valued at $202,075 was sold by Goodell Timothy B.. Another trade for 11,726 shares valued at $449,927 was sold by Hill Gregory P.. 1,919 shares valued at $85,261 were sold by Lowery-Yilmaz Barbara J on Thursday, February 8. HESS JOHN B sold $4.15 million worth of stock or 93,712 shares. RIELLY JOHN P sold 3,382 shares worth $150,262.
Price Michael F, which manages about $722.19M US Long portfolio, upped its stake in The Macerich Company (NYSE:MAC) by 11,900 shares to 50,000 shares, valued at $2.75 million in 2017Q3, according to the filing. It also increased its holding in Trinity Place Holdings Inc. (TPHS) by 124,591 shares in the quarter, for a total of 4.26 million shares, and has risen its stake in Fsb Bancorp.
Investors sentiment decreased to 0.88 in 2017 Q3. Its down 0.12, from 1 in 2017Q2. It dived, as 43 investors sold HES shares while 162 reduced holdings. 48 funds opened positions while 133 raised stakes. 254.48 million shares or 1.67% more from 250.30 million shares in 2017Q2 were reported. Fifth Third Bancorp accumulated 187 shares. Investec Asset Mgmt North America invested in 26,363 shares or 0.21% of the stock. Strs Ohio reported 1.17 million shares. Whittier Of Nevada Inc stated it has 34,595 shares. Dimensional Fund Advisors Ltd Partnership holds 2.43 million shares. Moreover, Orrstown Svcs has 0% invested in Hess Corporation (NYSE:HES) for 32 shares. Reaves W H And Inc accumulated 82,250 shares. Campbell & Communications Inv Adviser Limited Liability reported 7,174 shares. Evercore Wealth Management Limited Liability has invested 0% in Hess Corporation (NYSE:HES). Wellington Gru Llp holds 16.13M shares. Barrow Hanley Mewhinney & Strauss Limited Liability Corporation holds 0.3% or 4.23 million shares in its portfolio. Cibc World holds 0.01% of its portfolio in Hess Corporation (NYSE:HES) for 30,139 shares. Bridgewater Associate Ltd Partnership reported 16,357 shares. Intact Invest Mgmt, a Ontario – Canada-based fund reported 27,900 shares. State Of Tennessee Treasury Department owns 86,158 shares.
Analysts await Hess Corporation (NYSE:HES) to report earnings on April, 25. They expect $-0.54 earnings per share, up 49.53% or $0.53 from last year’s $-1.07 per share. After $-1.01 actual earnings per share reported by Hess Corporation for the previous quarter, Wall Street now forecasts -46.53% EPS growth.
Among 14 analysts covering Abiomed (NASDAQ:ABMD), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Abiomed had 33 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Buy” rating by Jefferies on Thursday, August 3. On Friday, October 30 the stock rating was upgraded by Raymond James to “Outperform”. Benchmark maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Tuesday, August 4. Benchmark has “Buy” rating and $96 target. Piper Jaffray maintained the shares of ABMD in report on Thursday, February 1 with “Buy” rating. The rating was maintained by Piper Jaffray with “Hold” on Wednesday, August 5. Jefferies maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Thursday, December 21. Jefferies has “Buy” rating and $220.0 target. Sterne Agee CRT initiated ABIOMED, Inc. (NASDAQ:ABMD) on Tuesday, August 18 with “Buy” rating. The firm earned “Buy” rating on Tuesday, June 6 by Jefferies. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Overweight” rating given on Thursday, April 6 by PiperJaffray. Jefferies maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Thursday, June 29. Jefferies has “Buy” rating and $16500 target.
Investors sentiment decreased to 1.3 in 2017 Q3. Its down 0.13, from 1.43 in 2017Q2. It dived, as 27 investors sold ABMD shares while 89 reduced holdings. 55 funds opened positions while 96 raised stakes. 38.51 million shares or 1.21% less from 38.99 million shares in 2017Q2 were reported. Commonwealth Equity Svcs Inc reported 2,324 shares. Balasa Dinverno Foltz Ltd Liability Corporation reported 2,366 shares stake. State Of Tennessee Treasury Department holds 0.03% or 30,000 shares. Ing Groep Nv owns 1,509 shares or 0% of their US portfolio. Price T Rowe Inc Md stated it has 0% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Castleark Management Limited Liability Co reported 339,961 shares or 1.8% of all its holdings. 83,398 are held by California Pub Employees Retirement System. The Washington-based Tradewinds Management Limited Com has invested 0.01% in ABIOMED, Inc. (NASDAQ:ABMD). Cap One National Association stated it has 0.03% in ABIOMED, Inc. (NASDAQ:ABMD). Invesco Limited owns 180,722 shares. Nicholas Investment Prns Limited Partnership invested in 71,114 shares. Palo Alto Investors Limited, California-based fund reported 1.94M shares. Messner & Smith Theme Value Mngmt Ca, a California-based fund reported 10,648 shares. 1832 Asset Mngmt LP holds 353,800 shares or 0.2% of its portfolio. Royal National Bank & Trust Of Canada accumulated 125,813 shares or 0.01% of the stock.